跳至主要内容
临床试验/TCTR20170612001
TCTR20170612001招募中3 期

A Prospective Randomized Controlled Clinical Trial of Prophylactic Cranial Irradiation in Metastatic HER-2 positive Breast Cancer.

Ratchadapiseksompotch research fund0 个研究点目标入组 235 人开始时间: 2017年6月12日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
235

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 0 N/A (No limit)(—)
性别
All

入选标准

  • 1.MetastaticHER-2 positive breast cancer patients who had HER-2 positive on immunohistochemistry or fluorescence in situ hybridization test.
  • 2.No brain metastasis is noted
  • 3.Eastern Cooperative Oncology Group (ECOG) performance status <=2
  • 4.More than 18 years of age.
  • 5.General physical conditions must be compatible with the radio-therapeutic treatment.
  • 6.Patients give permissions literally in the study informed consent form prior to participation.
  • 7. The blood tests have to be fulfilled of WBC >=3000, platelet >=100,000, creatinine <=1.5 mg/do, creatinine clearance >=60ml/min

排除标准

  • 1. History of previous cranial radiation or neurosurgery
  • 2 .History of cerebrovascular disease or neurological disorder including seizure.
  • 3 .Known or suspected brain or meningeal metastasis by present of signs of raised intra-cranial pressure, seizure, focal symptom, cognitive dysfunction and proved by MRI to have brain metastases.
  • 4 .Patient with CNS disease.
  • 5 .Active untreated infection which increases risk of treatment complication.
  • 6 .Major medical or psychiatric illnesses that would affect to the outcome, completion of therapy, the follow up and without potential in understand the side effects and risks of the therapy.
  • 7 .pregnant women.

研究者

发起方
Ratchadapiseksompotch research fund

相似试验

A Prospective Randomized Controlled Clinical Trial... | 临床试验